Authors: Florian J et al.
Anesthesiology, March 2026, 10.1097/ALN.0000000000006043
Summary
This randomized, double-blind, 3-period crossover trial looked at whether chronic SSRI therapy changes ventilatory response to hypercapnia, either by itself or when combined with oxycodone. Healthy volunteers received paroxetine, escitalopram, and placebo in separate treatment periods, with oxycodone 10 mg added on study days 6, 12, and 21. Ventilation was assessed with hyperoxic-hypercapnic rebreathing.
The main finding was that both paroxetine and escitalopram reduced hypercapnic ventilatory response after 21 days, and that effect was present both when the SSRI was given alone and when it was combined with oxycodone. Compared with oxycodone alone on day 21, paroxetine plus oxycodone lowered ventilation by 6.5 L/min and escitalopram plus oxycodone lowered it by 5.5 L/min. Importantly, the SSRIs also reduced ventilation even without oxycodone compared with placebo, with decreases of 6.5 L/min for paroxetine and 6.9 L/min for escitalopram.
That matters because prior concern had centered mainly on paroxetine and on shorter-term exposure. This trial suggests the effect is not limited to one drug and may represent more of an SSRI class effect that persists with chronic administration. Even though this was done in healthy volunteers rather than surgical patients or chronic pain patients, the signal is clinically important because many patients receiving opioids also take SSRIs.
The study does not prove actual clinical respiratory arrest risk in real-world patients, but it does show a measurable physiologic reduction in the ability to increase ventilation in response to hypercapnia. That raises concern that patients on chronic SSRIs may have less respiratory reserve when exposed to opioids.
Key Points
- Both paroxetine and escitalopram reduced hypercapnic ventilatory response after 21 days.
- The reduction occurred both with the SSRI alone and with SSRI plus oxycodone.
- This supports a possible SSRI class effect rather than a paroxetine-only effect.
- The findings are physiologic, not direct proof of worse clinical outcomes, but they strengthen concern about opioid-related respiratory depression in patients taking SSRIs.
- Anesthesiologists should at least be aware that chronic SSRI use may blunt ventilatory response when opioids are given.
What You Should Know
This is a useful paper because it pushes the discussion beyond simple CYP-mediated oxycodone interactions and suggests a broader respiratory effect of SSRIs themselves. For perioperative practice, it does not mean SSRIs should routinely be stopped, but it does support heightened awareness when opioids are administered, especially in patients who already have limited respiratory reserve, sleep-disordered breathing, obesity, or other sedating co-medications. The paper is more about risk recognition than immediate practice change, but it is a meaningful physiologic warning sign.
Thank you to Anesthesiology for allowing us to summarize this article.